Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersoMed-I: Sonidegib in Medulloblastoma
NCT04402073Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Allosteric Modulators
- Countries
- 8
01
Overview
A Phase 2 trial of sonidegib in medulloblastoma, sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2022; status: terminated.
02
Drugs
sonidegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04402073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402073.